TrialHeadache2020

Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.

Stewart J Tepper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.